Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2576056 | The American Journal of Geriatric Pharmacotherapy | 2006 | 17 Pages |
Abstract
Despite the well-documented selectivity of rasagiline, the manufacturer recommends virtually all of the dietary (vis-Ã -vis tyramine) and drug restrictions of the nonselective MAO inhibitors. Although useful, selective MAO-B inhibitors have a limited role in Parkinson's disease. Of greater interest is the potential neuroprotective effect of rasagiline and its major metabolite, 1(R)-aminoindan, which may have great utility in a wide variety of neurodegenerative disorders of aging. In addition, bifunctional molecules combining selective MAO-B inhibition (based on the active moiety of rasagiline) with acetylcholinesterase inhibition or iron chelation may eventually be useful in Alzheimer's disease.
Related Topics
Health Sciences
Medicine and Dentistry
Geriatrics and Gerontology
Authors
PharmD Guay,